PTCT
NASDAQPTC Therapeutics Inc.
News · 26 weeks66+25%
2026-04-192026-10-11
Mix2990d
- Insider13(45%)
- SEC Filings5(17%)
- Other4(14%)
- Earnings3(10%)
- Analyst3(10%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by PTC Therapeutics Inc.4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- ANALYSTTruist initiated coverage on PTC Therapeutics with a new price targetTruist initiated coverage of PTC Therapeutics with a rating of Hold and set a new price target of $62.00
- PRPTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commerc
- INSIDERSEC Form 4 filed by PTC Therapeutics Inc.4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by PTC Therapeutics Inc.4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by PTC Therapeutics Inc.4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Steele Glenn Jr Md Phd exercised 12,000 shares at a strike of $11.23 and sold $781,920 worth of shares (12,000 units at $65.16) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an aggregate of 51,270 shares of its common stock and 37,995 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 37 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on Sept. 22, 2026, and are being made as an inducement ma
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy– Completion of BLA submission expected in Q4 2026 –WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026. "Our team looks forward to completing the ST-920 BLA submission and potentially bringing a one-time administered, safe and effective durable disease treatment that addresses the limitations of chronic enzyme replacement therapy to the Fabry community," said Matthew
- INSIDERDirector Schmertzler Michael sold $1,349,728 worth of shares (20,000 units at $67.49) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- ANALYSTLeerink Partners resumed coverage on PTC Therapeutics with a new price targetLeerink Partners resumed coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $98.00
- ANALYSTLeerink Partners resumed coverage on PTC Therapeutics with a new price targetLeerink Partners resumed coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $133.00
- INSIDERDirector Schmertzler Michael sold $1,351,803 worth of shares (20,000 units at $67.59) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Schmertzler Michael sold $1,806,509 worth of shares (25,000 units at $72.26) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics to Participate in Upcoming Investor ConferencesWARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare ConferenceThursday, Sept. 10 at 9:30 a.m. ET2026 Cantor Global Healthcare ConferenceFriday, Sept. 11 at 8:35 a.m. ETMorgan Stanley 24th Annual Global Healthcare ConferenceTuesday, Sept. 15 at 9:15 a.m. ETThe presentations will be webcast live on the Events and Presentations page under the Investor section of the PTC Therapeutics website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentati
- PRPTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile– 17 abstracts and presentations planned at SSIEM Symposium –– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clin
- INSIDERDirector Schmertzler Michael sold $1,805,411 worth of shares (25,000 units at $72.22) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 2,813 shares at a strike of $25.69 and sold $204,127 worth of shares (2,813 units at $72.57) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile –– BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 –– PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $705,722 worth of shares (10,292 units at $68.57), decreasing direct ownership by 3% to 383,868 units (SEC Form 4) to cover taxes4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Sollie-Zetlmayer Hege Elisabeth was granted 6,000 shares, increasing direct ownership by 13% to 52,526 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERNew insider Sollie-Zetlmayer Hege Elisabeth claimed ownership of 46,526 shares (SEC Form 3)3 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
PTCT FAQ
7 questionsWhat does PTC Therapeutics Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States...Where does PTCT stock trade?
PTC Therapeutics Inc. (PTCT) is listed on NASDAQ.What sector and industry is PTCT in?
PTC Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PTC Therapeutics Inc. go public?
PTC Therapeutics Inc. (PTCT) completed its IPO in 2013.What are analysts saying about PTCT?
PTC Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Hold on 2026-10-16.What companies are similar to PTCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PTCT side-by-side with any of them on Quantisnow.How can I track PTCT on Quantisnow?
Quantisnow aggregates PTC Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTCT to receive live email and push alerts on every new disclosure.